PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.\', \'Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.\', \'Department of Oncology, Oxford University, Oxford, UK.\', \'Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom; Wellcome Centre for Human Genetics, Nuffield Dept of Medicine, Oxford University, OX3 7BN, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0264-410X(21)00807-010.1016/j.vaccine.2021.06.057
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 34253420
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34253420>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34253420>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all